All In Biotech

Drug Trial Radar · NCT01140217

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System

Last checked: Nov 20, 2026Latest source record: Sep 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,659

Actual

Start

May 2010

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Watson PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.

Conditions

  • Contraceptive Usage

Interventions

  • Norethindrone AcetateDrug

    Norethindrone Acetate Transdermal Delivery System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy RateTime frame: 1 year

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Watson Investigational Site

    Birmingham, Alabama

  • Watson Investigational Site

    Mobile, Alabama

  • Watson Investigational Site

    Montgomery, Alabama

  • Watson Investigational Site

    Chandler, Arizona

  • Watson Investigational Site

    Little Rock, Arkansas

  • Watson Investigational Site

    Garden Grove, California

  • Watson Investigational Site

    La Mesa, California

  • Watson Investigational Site

    San Diego, California

  • Watson Investigational Site

    Denver, Colorado

  • Watson Investigational Site

    Newark, Delaware

  • Watson Investigational Site

    Washington D.C., District of Columbia

  • Watson Investigational Site

    Aventura, Florida

  • Watson Investigational Site

    Daytona Beach, Florida

  • Watson Investigational Site

    Jacksonville, Florida

  • Watson Investigational Site

    Lake Worth, Florida

  • Watson Investigational Site

    Miami, Florida

  • Watson Investigational Site

    North Miami, Florida

  • Watson Investigational Site

    Pinellas Park, Florida

  • Watson Investigational Site

    Sarasota, Florida

  • Watson Investigational Site

    Atlanta, Georgia

  • Watson Investigational Site

    Decatur, Georgia

  • Watson Investigational Site

    Sandy Springs, Georgia

  • Watson Investigational Site

    Savannah, Georgia

  • Watson Investigational Site

    Chicago, Illinois

  • Watson Investigational Site

    Overland Park, Kansas

  • Watson Investigational Site

    Marrero, Louisiana

  • Watson Investigational Site

    New Orleans, Louisiana

  • Watson Investigational Site

    Haverhill, Massachusetts

  • Watson Investigational Site

    Ann Arbor, Michigan

  • Watson Investigational Site

    Kalamazoo, Michigan

  • Watson Investigational Site

    Edina, Minnesota

  • Watson Investigational Site

    Las Vegas, Nevada

  • Watson Investigational Site

    Lawrenceville, New Jersey

  • Watson Investigational Site

    Albuquerque, New Mexico

  • Watson Investigational Site

    New York, New York

  • Watson Investigational Site

    Chapel Hill, North Carolina

  • Watson Investigational Site

    New Bern, North Carolina

  • Watson Investigational Site

    Raleigh, North Carolina

  • Watson Investigational Site

    Cleveland, Ohio

  • Watson Investigational Site

    Columbus, Ohio

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.